Lumateperone rapidly reduces bipolar mania in phase 3 trial

Clinical takeaway: Lumateperone is still investigational for bipolar mania. If confirmed and approved, its rapid effect could add an acute-mania option for patients with bipolar I disorder, including those who have received the drug for bipolar depression.

Acute mania can escalate quickly, compromise safety, and require hospitalization, making rapid symptom control a priority. Available treatments vary in effectiveness and tolerability, leaving a need for additional options.

Lumateperone is already FDA-approved for bipolar depression, but not mania. In the phase 3 Study 451, 354 adults with bipolar I disorder and a current manic episode, with or without mixed features, were randomized to once-daily lumateperone 42 mg or placebo for three weeks.

According to topline findings reported by Johnson & Johnson, lumateperone reduced manic symptoms significantly more than placebo at week 3, with a moderate-to-large treatment effect. Improvement was apparent by day 3 and continued through week 3.

Clinical response, defined as at least a 50% reduction in mania scores, occurred in 45.8% of the lumateperone group versus 20.9% of the placebo group. Overall illness severity also improved significantly.

The most common treatment-related adverse events were dry mouth and nausea, each reported in 7.9% of lumateperone-treated patients. Detailed safety and discontinuation data have not yet been released.

If the findings are replicated, lumateperone could offer clinicians an option with evidence across both depressive and manic episodes of bipolar I disorder. However, the three week trial does not establish maintenance efficacy or long-term safety.

“These results are encouraging because Caplyta not only significantly improved the symptoms of mania, but did so as early as day 3,” said Michael E. Thase, MD, of the University of Pennsylvania, who has provided consulting, advisory, and speaking services to Johnson & Johnson.

A second pivotal phase 3 trial has been completed, with data analysis underway. Full results from both studies and regulatory review will be needed to determine whether lumateperone’s indication should expand to acute bipolar mania.

Source: Johnson & Johnson. (2026 Sept 21). Caplyta (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study